Demographic and Clinical Characteristics of 907 Cases with Naltrexone Intoxication; a 14-Year Cross-Sectional Study.  Rahimi M, Kargar A, Hazegh Fetratjoo D, Hosseini SM, Mahdavinejad A, Shadnia S.  Arch Acad Emerg Med. 2022 May 1;10(1...

HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a non-blinded, randomized non-inferiority trial.  Korthuis, PT, Cook, RR, Lum, PJ, Waddell, EN, Tookes, H...

Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.  Shulman M, Hu MC, Sullivan MA, Akerman SC, Fratantonio J, Barbieri V, Nunes EV, Bisaga A.  Drug Alcohol Depend. 2022 Apr 1...

Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018.  Jain P, McKinnell K, Marino R, Vunnava P, Liles-Burden MA, Desai A, Wenten M, Fratantonio J, Akerman SC, Sulli...

Gender differences among criminal justice-involved persons living with HIV interested in extended-release naltrexone treatment.  Biondi BE, Frank CA, Forray A, Springer SA.  Subst Abus. 2021;42(4):905-911. doi: 10.1080/08897077.2021.19...

Patient characteristics associated with initiation of XR-naltrexone for opioid use disorder in clinical trials.  Shulman M, Hu MC, Sullivan MA, Akerman SC, Fratantonio J, Barbieri V, Nunes EV, Bisaga A.  Drug Alcohol Depend. 2022 Feb 2...